{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:20:42Z","timestamp":1769127642471,"version":"3.49.0"},"reference-count":39,"publisher":"Portland Press Ltd.","issue":"4","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:p>Increase in the apoptotic molecule Fas ligand (FasL) in serum and cardiomyocytes has been shown to be associated with progressive dilated cardiomyopathy (DCM) and congestive heart failure (CHF) in humans. However, the underlying mechanism(s) of FasL-related deterioration of heart function remain obscure. The aim of the present study is to determine roles of myocardial FasL in the activation of alternative pathways such as extracellular-signal-regulated kinase 1\/2 (ERK1\/2), inflammation or fibrosis and to identify effective treatments of progressive DCM and advanced CHF. Transgenic mice with cardiomyocyte-specific overexpression of FasL were investigated and treated with an ERK1\/2 inhibitor (U-0126), losartan (los), prednisolone (pred) or placebo. Morpho-histological and molecular studies were subsequently performed. FasL mice showed significantly higher mortality compared with wild-type (WT) littermates due to DCM and advanced CHF. Prominent perivascular and interstitial fibrosis, increased interleukin secretion and diffuse CD3-positive cell infiltration were evident in FasL hearts. Up-regulation of the short form of Fas-associated death domain (FADD)-like interleukin 1\u03b2-converting enzyme (FLICE) inhibitory protein (s-FLIP), RIP (receptor-interacting protein) and ERK1\/2 and down-regulation of transforming growth factor beta 1 (TGF\u03b21) and nuclear factor-\u03baB (NF-\u03baB) was determined in the myocardium, whereas expression of ERK1\/2, periostin (Postn) and osteopontin increased in cardiac fibroblasts. U-0126 and los increased CHF survival by 75% compared with pred and placebo groups. U-0126 had both anti-fibrotic and anti-apoptotic effects, whereas los reduced fibrosis only. Myocardial FasL expression in mice activates differential robust fibrotic, apoptotic and inflammatory responses via ERK1\/2\u00a0in cardiomyocytes and cardiac fibroblasts inducing DCM and CHF. Blocking the ERK1\/2 pathway prevented progression of FasL-induced DCM and CHF by reducing fibrosis, inflammation and apoptosis in the myocardium.<\/jats:p>","DOI":"10.1042\/cs20150624","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T02:03:37Z","timestamp":1447466617000},"page":"289-299","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["FasL expression in cardiomyocytes activates the ERK1\/2 pathway, leading to dilated cardiomyopathy and advanced heart failure"],"prefix":"10.1042","volume":"130","author":[{"given":"Anne-Cecile","family":"Huby","sequence":"first","affiliation":[{"name":"Texas Heart Institute, Regenerative Medicine Research, Houston, TX 77030, U.S.A."},{"name":"Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subat","family":"Turdi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A."},{"name":"Department of Pediatrics, The Heart Institute, University of Tennessee Health Science Center, Memphis, TN 38103, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"James","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey\u00a0A.","family":"Towbin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A."},{"name":"Department of Pediatrics, The Heart Institute, University of Tennessee Health Science Center, Memphis, TN 38103, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enkhsaikhan","family":"Purevjav","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A."},{"name":"Department of Pediatrics, The Heart Institute, University of Tennessee Health Science Center, Memphis, TN 38103, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2016,1,14]]},"reference":[{"key":"2021113010444468700_B1","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/CIRCULATIONAHA.104.500546","article-title":"Mechanisms and models in heart failure: the biomechanical model and beyond","volume":"111","author":"Mann","year":"2005","journal-title":"Circulation"},{"key":"2021113010444468700_B2","doi-asserted-by":"crossref","first-page":"IV14","DOI":"10.1161\/01.CIR.102.suppl_4.IV-14","article-title":"Congestive heart failure: fifty years of progress","volume":"102","author":"Braunwald","year":"2000","journal-title":"Circulation"},{"key":"2021113010444468700_B3","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021113010444468700_B4","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.jacc.2011.06.058","article-title":"New targets to treat the structural remodeling of the myocardium","volume":"58","author":"Gonz\u00e1lez","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010444468700_B5","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S0002-9149(99)00133-2","article-title":"Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure","volume":"83","author":"Yamaguchi","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"2021113010444468700_B6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12012-007-9004-9","article-title":"Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy","volume":"7","author":"Purevjav","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"key":"2021113010444468700_B7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0008-6363(97)00323-4","article-title":"Expression of apoptosis-related proteins in experimental coxsackievirus myocarditis","volume":"38","author":"Colston","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"2021113010444468700_B8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1172\/JCI13779","article-title":"Fas receptor signaling inhibits glycogen synthase kinase 3\u03b2 and induces cardiac hypertrophy following pressure overload","volume":"109","author":"Badorff","year":"2002","journal-title":"J. Clin. Invest."},{"key":"2021113010444468700_B9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1161\/01.CIR.102.8.915","article-title":"Involvement of CD95\/Apo1\/Fas in cell death after myocardial ischemia","volume":"102","author":"Jeremias","year":"2000","journal-title":"Circulation"},{"key":"2021113010444468700_B10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1161\/01.CIR.102.5.572","article-title":"Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in\u00a0vivo study","volume":"102","author":"Nakamura","year":"2000","journal-title":"Circulation"},{"key":"2021113010444468700_B11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1161\/01.CIR.101.10.1172","article-title":"The cardiac Fas (APO-1\/CD95) Receptor\/Fas ligand system : relation to diastolic wall stress in volume-overload hypertrophy in\u00a0vivo and activation of the transcription factor AP-1\u00a0in cardiac myocytes","volume":"101","author":"Wollert","year":"2000","journal-title":"Circulation"},{"key":"2021113010444468700_B12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1172\/JCI8212","article-title":"Proinflammatory consequences of transgenic fas ligand expression in the heart","volume":"105","author":"Nelson","year":"2000","journal-title":"J. Clin. Invest."},{"key":"2021113010444468700_B13","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/eji.1830241032","article-title":"T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A","volume":"24","author":"Anel","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"2021113010444468700_B14","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/j.ijcard.2013.01.163","article-title":"Cardiomyocyte apoptosis in the failing heart\u2013a critical review from definition and classification of cell death","volume":"167","author":"Takemura","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2021113010444468700_B15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0960-9822(00)00512-1","article-title":"The caspase-8 inhibitor FLIP promotes activation of NF-[kappa]B and Erk signaling pathways","volume":"10","author":"Kataoka","year":"2000","journal-title":"Curr. Biol."},{"key":"2021113010444468700_B16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/sj.embor.embor854","article-title":"The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases","volume":"4","author":"Devin","year":"2003","journal-title":"EMBO Rep."},{"key":"2021113010444468700_B17","doi-asserted-by":"publisher","first-page":"e55427","DOI":"10.1371\/journal.pone.0055427","article-title":"Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model","volume":"8","author":"Gay-Jordi","year":"2013","journal-title":"PLoS One"},{"key":"2021113010444468700_B18","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1128\/MCB.18.12.7243","article-title":"Tissue-restricted expression of the cardiac \u03b1-myosin heavy chain gene is controlled by a downstream repressor element containing a palindrome of two Ets-binding sites","volume":"18","author":"Gupta","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"2021113010444468700_B19","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(02)08026-1","article-title":"Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy","volume":"359","author":"Vatta","year":"2002","journal-title":"Lancet"},{"key":"2021113010444468700_B20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0008-6363(99)00023-1","article-title":"Mechanisms of remodeling of gap junction distributions and the development of anatomic substrates of arrhythmias","volume":"42","author":"Saffitz","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"2021113010444468700_B21","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1074\/jbc.274.3.1541","article-title":"The role of c-FLIP in modulation of CD95-induced apoptosis","volume":"274","author":"Scaffidi","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2021113010444468700_B22","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1093\/ndt\/gfn171","article-title":"The great escape\u2014myofibroblasts in fibrosis and the immune system","volume":"23","author":"Strutz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113010444468700_B23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1152\/physrev.00008.2011","article-title":"Matricellular proteins in cardiac adaptation and disease","volume":"92","author":"Frangogiannis","year":"2012","journal-title":"Physiol. Rev."},{"key":"2021113010444468700_B24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1152\/physiolgenomics.00071.2010","article-title":"Influence of genetic background on ex vivo and in\u00a0vivo cardiac function in several commonly used inbred mouse strains","volume":"42A","author":"Barnabei","year":"2010","journal-title":"Physiol. Genomics"},{"key":"2021113010444468700_B25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10741-010-9168-4","article-title":"Proinflammatory cytokines in heart failure: double-edged swords","volume":"15","author":"Hedayat","year":"2010","journal-title":"Heart Fail. Rev."},{"key":"2021113010444468700_B26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/RES.0b013e3182582523","article-title":"Animal models of heart failure: a scientific statement from the American Heart Association","volume":"111","author":"Houser","year":"2012","journal-title":"Circ. Res."},{"key":"2021113010444468700_B27","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1016\/j.biocel.2009.08.002","article-title":"Cardiac hypertrophy: targeting Raf\/MEK\/ERK1\/2-signaling","volume":"41","author":"Lorenz","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2021113010444468700_B28","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM199610173351603","article-title":"Apoptosis in myocytes in end-stage heart failure","volume":"335","author":"Narula","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"2021113010444468700_B29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/01.CIR.103.5.670","article-title":"Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure","volume":"103","author":"Haq","year":"2001","journal-title":"Circulation"},{"key":"2021113010444468700_B30","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/01.CIR.0000088782.99568.CA","article-title":"Regional alterations in protein expression in the dyssynchronous failing heart","volume":"108","author":"Spragg","year":"2003","journal-title":"Circulation"},{"key":"2021113010444468700_B31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy","volume":"1","author":"Shimada","year":"2013","journal-title":"JACC Heart Fail."},{"key":"2021113010444468700_B32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5339\/gcsp.2015.7","article-title":"INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy-a Randomised Intervention Trial with losartan)","volume":"2015","author":"Olivotto","year":"2015","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"2021113010444468700_B33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1161\/01.RES.0000204724.29685.db","article-title":"Upregulated TRPC1 channel in vascular injury in\u00a0vivo and its role in human neointimal hyperplasia","volume":"98","author":"Kumar","year":"2006","journal-title":"Circ. Res."},{"key":"2021113010444468700_B34","first-page":"173","article-title":"Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure","volume":"8","author":"Zhang","year":"2003","journal-title":"Exp. Clin. Cardiol."},{"key":"2021113010444468700_B35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1749-6632.2009.05088.x","article-title":"Extracellular signal-regulated kinase 1\/2 (ERK1\/2) signaling in cardiac hypertrophy","volume":"1188","author":"Kehat","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2021113010444468700_B36","first-page":"1","article-title":"Regulation of renin release by local and systemic factors","volume":"161","author":"Schweda","year":"2011","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"2021113010444468700_B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.regpep.2005.06.007","article-title":"Activation of protein kinase A by atrial natriuretic peptide in neonatal rat cardiac fibroblasts: role in regulation of the local renin-angiotensin system","volume":"132","author":"Sanghi","year":"2005","journal-title":"Regul. Pept."},{"key":"2021113010444468700_B38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1095\/biolreprod65.3.799","article-title":"Angiotensin II and atrial natriuretic peptide in the cow oviductal contraction in\u00a0vitro: direct effect and local secretion of prostaglandins, endothelin-1, and angiotensin II","volume":"65","author":"Wijayagunawardane","year":"2001","journal-title":"Biol. Reprod."},{"key":"2021113010444468700_B39","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/0092-8674(93)90541-W","article-title":"Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in\u00a0vitro","volume":"75","author":"Sadoshima","year":"1993","journal-title":"Cell"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/130\/4\/289\/444356\/cs1300289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/130\/4\/289\/444356\/cs1300289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:33:18Z","timestamp":1638271998000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/130\/4\/289\/71462\/FasL-expression-in-cardiomyocytes-activates-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,14]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20150624","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,14]]}}}